In This Article:
CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will present three related posters at the upcoming 2025 Digestive Disease Week (DDW) Conference being held May 3-6, 2025, in San Diego, CA.
Seres previously reported exploratory translational biomarker data from its SER-155 Phase 1b study, which provided evidence supporting the intended therapeutic mechanisms. These included promoting intestinal epithelial barrier integrity to reduce the translocation of bacteria and inflammatory bacterial products into the bloodstream, as well as modulating systemic inflammatory responses. New results presented at the DDW conference could help identify candidate biomarkers to support the further clinical development of live biotherapeutics to treat inflammatory and immune diseases, including ulcerative colitis and Crohn’s disease.
Seres is currently seeking partnership opportunities to advance the development of its biotherapeutics in inflammatory and immune diseases.
Presentation Details - New Research
Title: Characterization of IBD microbiomes in Models of Microbiome Disruption and Inflammation to Evaluate Candidate Biomarkers for Patient Selection
Abstract Number: Sa1770
Presenter: Nicholas Beauchemin, Principal Scientist, R&D
Date & Time: May 3, 2025 from 12:30 PM to 1:30 PM
Title: Candidate Biomarkers of Microbiome Disruption for Patient Selection or Stratification in Clinical Trials of Microbiome Therapeutics in Ulcerative Colitis (UC)
Abstract Number: Sa1767
Presenter: Nicholas Beauchemin, Principal Scientist, R&D
Date & Time: May 3, 2025 from 12:30 PM to 1:30 PM
Presentation Details - Encore of Previously Disclosed Results
Title: Pharmacokinetic (PK) and pharmacodynamic (PD) results from a randomized, double-blind, placebo-controlled Cohort 2 of a Phase 1b study of an investigational, oral, live biotherapeutic, SER-155, in adults undergoing allo-HCT
Abstract Number: Su2009
Presenter: Christopher Ford, SVP, R&D
Date & Time: May 4, 2025 from 12:30 PM to 1:30 PM
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting from May 3-6, 2025. The meeting showcases nearly 6,000 abstracts and over 1,000 invited talks on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.